Influvac

Influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It stimulates the immune system to produce antibodies against selected influenza virus strains, helping to prevent seasonal flu in individuals six months of age and older, and is recommended annually.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Influvac is an inactivated influenza vaccine that targets the influenza virus family to prevent seasonal flu, and it is administered annually to maintain immunity. - Seasonal influenza (all strains): reduces risk of infection and severity. - Influenza B (B/Austria/1359417/2021): induces protective antibodies against the B strain. - Influenza A (A/Vic): induces protective antibodies against the A/Vic strain. - High‑risk groups (elderly, chronic disease): lowers hospitalization and complications from flu. - Children (6 months–5 years): provides early protection against circulating influenza strains. - Pregnant women: helps protect mother and newborn from influenza complications.

Common side effects are generally mild and resolve without intervention.

Common Side Effects: - Injection site pain, redness, or swelling. - Low‑grade fever (up to 38°C). - Headache. - Muscle aches. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Guillain‑Barré syndrome. - High fever (>40°C). - Seizures. - Immune‑mediated thrombocytopenia.

Precautions should be observed to minimise risk and ensure optimal vaccine performance. - Allergy screening: avoid in persons with known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination in individuals with moderate or severe feverish illness. - Pregnancy: consult a healthcare provider; use only if benefits outweigh potential risks. - Immunocompromised patients: vaccine may be less effective; consider alternative protective measures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents, affecting immune response or safety.

Major Interactions (Avoid): - Prior severe allergic reaction to any component of Influvac. - Concomitant administration with live attenuated vaccines without appropriate interval. - Use of investigational vaccines targeting the same strains.

Moderate Interactions (Monitor Closely): - Prophylactic antipyretics (e.g., acetaminophen) may blunt antibody response. - Ongoing immunosuppressive therapy may reduce vaccine efficacy. - Recent receipt of blood products could interfere with immune activation. - Seasonal antiviral medications may modestly affect immunogenicity.